By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Catalyst Biosciences, Inc. 

260 Littlefield Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-871-0761 Fax: n/a



Company News
Catalyst Biosciences Completes Merger With Targacept (TRGT) And Creates A Protease-Based Hemostasis And Anti-Complement Company 8/21/2015 7:30:06 AM
Targacept (TRGT) Announces Stockholder Approval Of Proposals Related To Merger With Catalyst Biosciences 8/19/2015 11:17:25 AM
Targacept (TRGT) Declares Pre-closing Dividend In Connection With Its Merger With Catalyst Biosciences 8/5/2015 10:57:18 AM
Catalyst Biosciences Announces Positive Results From A Phase 1 Clinical Trial Of Its Next Generation Coagulation Factor VIIa In Patients With Hemophilia A Or B And Preclinical Results From Its Factor IX And Factor Xa Programs 6/24/2015 7:47:41 AM
Catalyst Biosciences To Present At The Jefferies and Co. 2015 Global Healthcare Conference 5/28/2015 7:27:59 AM
Targacept (TRGT) And Catalyst Biosciences Amend Definitive Merger Agreement 5/14/2015 8:35:23 AM
Bay Area's Catalyst Biosciences to Merge With Unlucky Targacept (TRGT) 3/6/2015 6:36:53 AM
Catalyst Biosciences, Inc. and ISU ABXIS CO., LTD Announce Collaboration to Develop Next-Generation Best-In-Class Factor IX Therapeutics 10/9/2013 9:50:09 AM
Pfizer Inc. (PFE) Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences, Inc. 1/5/2012 10:56:23 AM
Catalyst Biosciences, Inc. Receives $4 Million Milestone Payment from Pfizer Inc. (PFE) for Progress in Lead Hemostasis Program 12/16/2010 6:42:47 AM